Wednesday, June 10, 2026

Patent directory · USPTO A61K / A61P

Patents matching “REGENERON PHARMACEUTICALS, INC.”

837 pharma patents match "REGENERON PHARMACEUTICALS, INC." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 837
Index total 30,257
Page 3 / 35

Quick answer

This filtered view shows 837 pharmaceutical patents matching "REGENERON PHARMACEUTICALS, INC." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

837 results for “REGENERON PHARMACEUTICALS, INC.” · 30,257 patents in full index Clear search

  1. US 12275792

    Antigen-binding proteins that activate the leptin receptor

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 15, 2025 · Expires Apr 10, 2045

    granted
  2. US 12274747

    Compositions and methods for treating cytokine release syndrome

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 15, 2025 · Expires Apr 10, 2045

    granted
  3. US 12268730

    Use of a VEGF antagonist to treat angiogenic eye disorders

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 8, 2025 · Expires Apr 3, 2045

    granted
  4. US 12269897

    Anti-PCSK9 antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 8, 2025 · Expires Apr 3, 2045

    granted
  5. US 12269889

    Human antibodies to the human glucagon receptor (HGCGR) and methods of use thereof to lower blood glucose or ketone levels

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 8, 2025 · Expires Apr 3, 2045

    granted
  6. US 12264343

    TCRa homing endonuclease variants

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 1, 2025 · Expires Mar 27, 2045

    granted
  7. US 12264366

    Genome-based methods for reducing cardiovascular risk

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 1, 2025 · Expires Mar 27, 2045

    granted
  8. US 12256720

    Humanized dipeptidyl-peptidase IV (DPP4) animals

    REGENERON PHARMACEUTICALS, INC. · Granted Mar 25, 2025 · Expires Mar 20, 2045

    granted
  9. US 12258412

    Nucleic acid molecules encoding bispecific anti-BCMA x anti-CD3 antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Mar 25, 2025 · Expires Mar 20, 2045

    granted
  10. US 12258627

    Kelch domain containing 7B (KLHDC7B) variants and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Mar 25, 2025 · Expires Mar 20, 2045

    granted
  11. US 12258597

    Methods and compositions for therapeutic protein delivery

    REGENERON PHARMACEUTICALS, INC. · Granted Mar 25, 2025 · Expires Mar 20, 2045

    granted
  12. US 12252544

    Anti-CD63 antibodies, conjugates, and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Mar 18, 2025 · Expires Mar 13, 2045

    granted
  13. US 12252520

    Myosin 15 promoters and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Mar 18, 2025 · Expires Mar 13, 2045

    granted
  14. US 12250931

    Genetically modified mouse with a humanized PNPLA3 gene and methods of use

    REGENERON PHARMACEUTICALS, INC. · Granted Mar 18, 2025 · Expires Mar 13, 2045

    granted
  15. US 12251440

    Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments

    REGENERON PHARMACEUTICALS, INC. · Granted Mar 18, 2025 · Expires Mar 13, 2045

    granted
  16. US 12252530

    Human antibodies to Fel d1 and methods of use thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Mar 18, 2025 · Expires Mar 13, 2045

    granted
  17. US 12240907

    N-terminal scFv multispecific binding molecules

    REGENERON PHARMACEUTICALS, INC. · Granted Mar 4, 2025 · Expires Feb 27, 2045

    granted
  18. US 12239687

    Sustained release formulations using non-aqueous membrane emulsification

    REGENERON PHARMACEUTICALS, INC. · Granted Mar 4, 2025 · Expires Feb 27, 2045

    granted
  19. US 12240908

    N-terminal scFv multispecific binding molecules

    REGENERON PHARMACEUTICALS, INC. · Granted Mar 4, 2025 · Expires Feb 27, 2045

    granted
  20. US 12234277

    Hydrophobic interaction chromatography for viral clearance

    REGENERON PHARMACEUTICALS, INC. · Granted Feb 25, 2025 · Expires Feb 20, 2045

    granted
  21. US 12234460

    Methods of treating decreased bone mineral density with cluster of differentiation 109 (CD109) inhibitors

    REGENERON PHARMACEUTICALS, INC. · Granted Feb 25, 2025 · Expires Feb 20, 2045

    granted
  22. US 12227740

    CBLB endonuclease variants, compositions, and methods of use

    REGENERON PHARMACEUTICALS, INC. · Granted Feb 18, 2025 · Expires Feb 13, 2045

    granted
  23. US 12230364

    Immunotherapy methods for patients whose tumors carry a high passenger gene mutation burden

    REGENERON PHARMACEUTICALS, INC. · Granted Feb 18, 2025 · Expires Feb 13, 2045

    granted
  24. US 12214023

    Compositions and methods for expressing factor IX

    REGENERON PHARMACEUTICALS, INC. · Granted Feb 4, 2025 · Expires Jan 30, 2045

    granted